Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs) EQUITY
$88.63
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | BMRN Avg Daily Volume: 1,257,000
Last Update: 07/25/17 - 4:00 PM EDT
Volume: 0
YTD Performance: 6.99%
Open: $0.00
Previous Close: $88.63
52 Week Range: $78.42 - $102.49
Oustanding Shares: 174,490,025
Market Cap: 15,705,847,150
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 12
Moderate Buy 2 2 2 2
Hold 2 2 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.37 1.37 1.47 1.44
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -26.63
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-26.63 0.00 31.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.90% -4.48% 46.25%
GROWTH 12 Mo 3 Yr CAGR
Revenue 25.50 1.00 0.26
Net Income 0.00 2.60 0.00
EPS 0.00 2.00 0.00
Earnings for BMRN:
EBITDA -0.16B
Revenue 1.12B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $-0.22 $-0.19 $-0.83 $-0.36
Number of Analysts 11 10 11 10
High Estimate $-0.12 $0.26 $-0.37 $0.46
Low Estimate $-0.34 $-0.29 $-1.00 $-0.96
Prior Year $-2.61 $-0.26 $-3.81 $-0.83
Growth Rate (Year over Year) 91.75% 28.46% 78.31% 56.68%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Jul 12, 2017 | 11:30 AM EDT
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
RMPIA
By

Bret Jensen

 | Jul 2, 2017 | 10:00 AM EDT
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
RMPIA
By

Bret Jensen

 | Jun 30, 2017 | 1:00 PM EDT
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
RMPIA
By

Jim Cramer

 | May 8, 2017 | 6:27 AM EDT
It's a wonder to me how split this market really is.
By

Bret Jensen

 | Apr 3, 2017 | 1:00 PM EDT
Home builders make up the second-largest allocation in my portfolio, behind biotech.
RMPIA
By

Bret Jensen

 | Jan 3, 2017 | 11:00 AM EST
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
By

Bruce Kamich

 | Nov 29, 2016 | 11:58 AM EST
The pharmaceutical stock is about to go from sideways to up.

bearishBiomarin downgraded at Piper

Nov 7, 2016 | 7:21 AM EST
BMRN was downgraded from Overweight to Neutral, Piper Jaffray said. $84 price target. Valuation call, given limited visibility.
By

James "Rev Shark" DePorre

 | Aug 22, 2016 | 10:40 AM EDT
Overall, this is still a good environment for stock picking.
By

Jim Cramer

 | Aug 8, 2016 | 7:28 PM EDT
They're striking while the iron is hottest to raise money, reduce debt.
Costco (COST) is beginning to firm up near the $150.00 area. The stock bottomed here at l...
We like this move today on good turnover and strong option flow. BOUGHT FCX OCT 15 CALL...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.